Posting of Annual Report & Notice of AGM

RNS Number : 0620M

EKF Diagnostics Holdings PLC

01 May 2015

 

1 May 2015

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

Posting of Annual Report & Notice of AGM

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care, central laboratory and molecular diagnostics business, confirms that the Annual Report and Accounts for the year ended 31 December 2014, the Notice of the Annual General Meeting and a Form of Proxy have been posted to shareholders.

The AGM is to be held on 19 May 2015 at the offices of Panmure Gordon, One New Change, London EC4M 9AF at 2pm.

A copy of the 2014 Annual Report and Accounts and other documents are available on the Company's website: http://www.ekfdiagnostics.com/

Enquiries:

EKF Diagnostics Holdings plc      Tel: [phone] David Evans, Executive Chairman Mob: [phone] Julian Baines, CEO  Mob: [phone] Paul Foulger, CFO Mob: [phone] Panmure Gordon (UK) Limited Robert Naylor (Corporate Finance) Tel: [phone] Michael Seabrook (Sales) Tel: [phone] Walbrook PR Limited  Tel: [phone] or [e-mail] Paul McManus Mob: [phone] Lianne Cawthorne Mob: [phone]

About EKF Diagnostics Holdings plc - www.ekfdiagnostics.com

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in September 2010), Argutus Medical Limited (acquired in December 2010) and Stanbio Laboratory L.P. (acquired in June 2011). In 2013 EKF established a new subsidiary, EKF Molecular Diagnostics Ltd, to focus on molecular and companion diagnostics and acquired 360 Genomics Ltd, a business that owns diagnostics technologies for cancer gene detection.

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focussing on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In March 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2. 

In March 2014, EKF acquired Separation Technology, Inc., a Florida based manufacturer of in vitro diagnostics devices for the haematology testing market. In April 2014, EKF completed the acquisitions of Selah Genomics Inc., a US based developer of molecular diagnostics for personalised medicine and DiaSpect Medical AB., a Swedish based manufacturer of point-of-care haemoglobin analysers.

 

END

 

 

MSCABMITMBBMBIA